Ginevra Giacomello

Dr. Ginevra Giacomello

Consiglio Nazionale delle Ricerche, IRET, Sesto Fiorentino, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
GGGinevra Giacomello
Ginevra Giacomello
ASAndreas Scholten
Andreas Scholten
MPMaria Kristina Parr
Maria Kristina Parr

6 October 2016 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
PDF file
AVAlessandro Venditti
Alessandro Venditti
ABArmandodoriano Bianco
Armandodoriano Bianco
Claudio FrezzaClaudio Frezza
Claudio Frezza
MSMauro Serafini
Mauro Serafini
GGGinevra Giacomello
Ginevra Giacomello
Filippo MaggiFilippo Maggi
Filippo Maggi

23 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CZCamila Fernández Zapata
Camila Fernández Zapata
GGGinevra Giacomello
Ginevra Giacomello
ESEike J. Spruth
Eike J. Spruth
JMJinte Middeldorp
Jinte Middeldorp
GGGerardina Gallaccio
Gerardina Gallaccio
CBChotima Böttcher
Chotima Böttcher
Myeloid cells are suggested as an important player in Alzheimer´s disease (AD). However, its continuum of phenotypic and functional changes across different body compartments and their use as a biomarker in AD remains elusive. Here, we perform multiple state-of-the-art analyses to phenotypically and metabolically characterize immune cells between peripheral blood (n = 117), cerebrospinal fluid (CSF, n = 117), choroid plexus (CP, n = 13) and brain parenchyma (n = 13). We find that CSF cells increase expression of markers involved in inflammation, phagocytosis, and metabolism. Changes in phenotype of myeloid cells from AD patients are more pronounced in CP and brain parenchyma and upon in vitro stimulation, suggesting that AD-myeloid cells are more vulnerable to environmental changes. Our findings underscore the importance of myeloid cells in AD and the detailed characterization across body compartments may serve as a resource for future studies focusing on the assessment of these cells as biomarkers in AD.

Verified
Journal Article
Open access
PDF file
GGGinevra Giacomello
Ginevra Giacomello
COCarolin Otto
Carolin Otto
JPJosef Priller
Josef Priller
KRKlemens Ruprecht
Klemens Ruprecht
CBChotima Böttcher
Chotima Böttcher
MPMaria Kristina Parr
Maria Kristina Parr
Neuroinflammation is one of the common features in most neurological diseases including multiple sclerosis (MScl) and neurodegenerative diseases such as Alzheimer’s disease (AD). It is associated with local brain inflammation, microglial activation, and infiltration of peripheral immune cells into cerebrospinal fluid (CSF) and the central nervous system (CNS). It has been shown that the diversity of phenotypic changes in monocytes in CSF relates to neuroinflammation. It remains to be investigated whether these phenotypic changes are associated with functional or metabolic alteration, which may give a hint to their function or changes in cell states, e.g., cell activation. In this article, we investigate whether major metabolic pathways of blood monocytes alter after exposure to CSF of healthy individuals or patients with AD or MScl. Our findings show a significant alteration of the metabolism of monocytes treated with CSF from patients and healthy donors, including higher production of citric acid and glutamine, suggesting a more active glycolysis and tricarboxylic acid (TCA) cycle and reduced production of glycine and serine. These alterations suggest metabolic reprogramming of monocytes, possibly related to the change of compartment (from blood to CSF) and/or disease-related. Moreover, the levels of serine differ between AD and MScl, suggesting different phenotypic alterations between diseases.

21 March 2025 in Agronomy
Verified
Journal Article
Open access
PDF file
DADavide Assandri
Davide Assandri
GGGinevra Giacomello
Ginevra Giacomello
ABAngela Bianco
Angela Bianco
Giacomo ZaraGiacomo Zara
Giacomo Zara
Marilena BudroniMarilena Budroni
Marilena Budroni
Niccolò PampuroNiccolò Pampuro
Niccolò Pampuro
The global production of brewers’ spent grains (BSG) is 37 million tons yearly. Composting represents an eco-friendly method to manage and valorize organic by-products in a circular economy model. This project aims to compare two BSG bin-composting mixtures (BSG and wheat straw with pig slurry solid fraction, MIX1, or sheep manure, MIX2) and approaches (manual turning, MT, and static composting, ST). The two mixtures’ physicochemical characteristics and greenhouse gas (GHG) emissions were assessed during the process. The evolution of physicochemical properties is reported in detail. Headspace samples of GHG emissions were collected and analyzed with gas chromatography coupled with specific detectors. Carbon dioxide (CO2) emissions were 34.3 ± 0.03 and 31.0 ± 0.06 g C kg−1 fresh matter (FM) for MIX1-MT and MIX2-MT, and 28.8 ± 0.01 and 31.2 ± 0.02 g Ckg−1 FM for MIX1-ST and MIX2-ST. Methane emissions were negligible (all conditions < 0.086 ± 0.00 mg C kg−1 FM). Nitrous oxide (N2O) emissions from composting are affected by the substrate, bulking material, pile dimension, and manure. Particularly, the total emissions of N2O, estimated as CO2 equivalents, were 45.8 ± 0.2 and 63.0 ± 0.4 g CO2 eq kg−1 FM for MIX1-MT and MIX1-ST, respectively. In both composting approaches, MIX2 showed a low CO2 equivalent (1.8 ± 0.02 and 9.9 ± 0.05 g CO2 eq kg−1 FM for MT and ST), likely due to incomplete decomposition. The bin-composting process represents a solution for recycling and reusing organic waste and livestock manure in small to medium-sized breweries. The solid fraction of the pig slurry resulted in the most suitable manure.

23 September 2022 in STAR Protocols
Verified
Journal Article
Open access
GGGinevra Giacomello
Ginevra Giacomello
CBChotima Böttcher
Chotima Böttcher
MPMaria Kristina Parr
Maria Kristina Parr
Differences in metabolic profiles can link to functional changes of immune cells in disease conditions. Here, we detail a protocol for the detection and quantitation of 19 metabolites in one analytical run. We provide the parameters for chromatographic separation and mass spectrometric analysis of isotopically labeled and unlabeled metabolites. We include steps for incubation and sample preparation of PBMCs and monocytes. This protocol overcomes the chromatographic challenges caused by the chelating properties of some metabolites.